Exclusively genital psoriasis successfully treated with Risankizumab. | Dermatol Ther;35(8): e15591, 2022 08. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Exclusively genital psoriasis successfully treated with Risankizumab.

Ceccarelli, Gabriele; Simonacci, Marco.

Ceccarelli G; Dermatology Unit, Macerata General Hospital, Macerata, Italy.
Simonacci M; Dermatology Unit, Macerata General Hospital, Macerata, Italy.

Dermatol Ther ; 35(8): e15591, 2022 08.

Article in English | MEDLINE | ID: covidwho-1985771

Subject(s)

Psoriasis; Antibodies, Monoclonal; Genitalia; Humans; Psoriasis/diagnosis; Psoriasis/drug therapy; Severity of Illness Index; Treatment Outcome

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15591

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15591